BiotechTube
Avesta76 Therapeutics

Avesta76 Therapeutics

Cambridge, United States· Est.
avestabio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Avesta76 Therapeutics is an early-stage oncology biotech startup aiming to redefine cancer care by developing therapeutics that promise a new standard of hope, potentially through enhanced safety profiles. Operating since 2016, the company is in the preclinical or discovery phase, building its pipeline and technology platform without yet generating revenue. As a private entity, its success hinges on advancing its research, securing venture funding, and translating its scientific vision into viable clinical candidates for a wide range of cancers.

Oncology

Technology Platform

Antibody-based therapeutic platform focused on oncology, aiming for high efficacy with improved safety/tolerability ('Hope Without Harm'). Specific modality (e.g., mAb, ADC, bispecific) not publicly disclosed.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

The global oncology market is large and growing, with a high demand for therapies that offer efficacy with reduced toxicity.
An antibody platform that successfully delivers a improved therapeutic index could address a major unmet need, enabling use in broader patient populations and combination regimens.
The company's Cambridge location provides excellent access to capital, talent, and collaboration opportunities.

Risk Factors

As a preclinical, private company, Avesta76 faces high scientific risk that its approach will not translate into effective drugs, and high financial risk in its dependence on venture funding in a competitive capital environment.
It also operates in the intensely competitive and crowded field of oncology antibody development against well-resourced competitors.

Competitive Landscape

Avesta76 competes in the highly saturated oncology antibody space, which includes global pharmaceutical giants (e.g., Roche, Merck, AstraZeneca) and numerous agile biotechs. Competition is based on target novelty, therapeutic efficacy, safety profile, and intellectual property. The company's differentiation, not yet publicly detailed, must be significant to attract investment and eventual partnership or commercial success.

More companies in Oncology (General) →More companies in United States →